1. Home >
  2. Companies >
  3. Private >
  4. Life Science >
  5. United States >
  6. PDL BioPharma >
  7. M&A

PDL BioPharma Mergers & Acquisitions

PDL BioPharma M&A Summary

PDL BioPharma has acquired 4 companies. A total of 1 acquisition came from private equity firms. It has also divested 1 asset.

It’s largest disclosed sale occurred in 2020, when it sold Noden Pharma DAC to Stanley Capital for $53M. PDL BioPharma has acquired in 2 different US states, and 2 countries. The Company’s most targeted sectors include life science (75%) and medical products (25%).

M&A Summary

  • M&A Total Activity5
    • M&A Buy Activity4
    • M&A Sell Activity1
  • Total Sectors Invested 2
  • Total Countries Invested 2
  • M&A Buy/Sell Connections 3

PDL BioPharma

PDL BioPharma, Inc.

932 Southwood Boulevard,
Incline Village, Nevada 89451
United States,
(775) 832-8500
www.pdl.com

All (5) Buy (4) Sell (1)
Date Target Value
$mlns 		Transaction Type Acquirer Seller SRC
Link
2020-09-09 Noden Pharma DAC · Life Science
Dublin, Ireland · www.nodenpharma.com

Noden Pharma DAC is a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a range of therapeutic areas. Noden Pharma DAC holds exclusive worldwide rights to manufacture, market, and sell Tekturna® and Tekturna HCT (or Rasilez and Rasilez HTC outside of the United States), which contain aliskiren, a direct renin inhibitor, for the treatment of hypertension. In March 2019, Noden announced the U.S commercial launch of an authorized generic form of Tekturna, aliskiren hemifumarate 150 mg, and 300 mg tablets with the same drug formulation as Tekturna. Noden Pharma DAC is headquartered in Dublin, Ireland.

53 Divestiture

Stanley Capital PE

PDL BioPharma


Try Mergr Free — See This and 221,398+
Other Company and Investor Profiles Today

Try free. Full access. Cancel anytime.

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
Try Free

What's Mergr?

Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.

We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.

With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.8K Private Equity Firms
  • 215K M&A Transactions
  • 217K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.8K M&A Advisors
    (Investment Banks and Law Firms)
  • 83K M&A Contacts
    (PE and M&A Advisors)

What next?

Try Free

Full access to Mergr's investor, acquirer, and transaction data starts here.

Mergr

Solution for

Product

Company

Legal